表紙
市場調査レポート

Ocular Therapeutix, Inc.の製品パイプライン分析

Ocular Therapeutix, Inc. - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 293961
出版日 ページ情報 英文 30 Pages
即納可能
価格
本日の銀行送金レート: 1USD=101.51円で換算しております。
Back to Top
Ocular Therapeutix, Inc.の製品パイプライン分析 Ocular Therapeutix, Inc. - Product Pipeline Review - 2015
出版日: 2015年11月18日 ページ情報: 英文 30 Pages
概要

Ocular Therapeutix, Inc.は米国に本社を置く医療機器企業で、ポリエチレングリコールを含むヒドロゲルの技術を利用した眼疾患の治療用製品を開発しています。涙点プラグや眼球後区への薬剤注入器、外科手術の際に利用される眼球用バンテージなどがパイプライン製品として挙げられます。

当レポートでは、Ocular Therapeutix, Inc.における治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

目次

Ocular Therapeutix, Inc.の基本情報

  • Ocular Therapeutix, Inc.の概要
  • 主要情報
  • 企業情報

Ocular Therapeutix, Inc.:R&Dの概要

  • 主な治療範囲

Ocular Therapeutix, Inc.:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品

Ocular Therapeutix, Inc.:パイプライン製品の概況

  • 後期段階にあるパイプライン製品
    • 第3相の製品/併用療法モダリティ
  • 臨床段階にあるパイプライン製品
    • 第2相の製品/併用療法モダリティ
    • 第1相の製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • 前臨床段階の製品/併用療法モダリティ

Ocular Therapeutix, Inc.:薬剤プロファイル

  • dexamethasone acetate SR
  • travoprost SR
  • moxifloxacin hydrochloride SR
  • Protein to Inhibit VEGF for Ophthalmology

Ocular Therapeutix, Inc.:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Ocular Therapeutix, Inc.:最新のパイプライン情報

Ocular Therapeutix, Inc.:本社と子会社の所在地

  • 本社

付録

図表一覧

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07777CDB

Summary

Global Markets Direct's, 'Ocular Therapeutix, Inc. - Product Pipeline Review - 2015', provides an overview of the Ocular Therapeutix, Inc.'s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Ocular Therapeutix, Inc.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Ocular Therapeutix, Inc. including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Ocular Therapeutix, Inc.'s human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Ocular Therapeutix, Inc.'s pipeline products

Reasons to buy

  • Evaluate Ocular Therapeutix, Inc.'s strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Ocular Therapeutix, Inc. in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Ocular Therapeutix, Inc.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Ocular Therapeutix, Inc. and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Ocular Therapeutix, Inc.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Ocular Therapeutix, Inc. and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Ocular Therapeutix, Inc. Snapshot
    • Ocular Therapeutix, Inc. Overview
    • Key Information
    • Key Facts
  • Ocular Therapeutix, Inc. - Research and Development Overview
    • Key Therapeutic Areas
  • Ocular Therapeutix, Inc. - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
  • Ocular Therapeutix, Inc. - Pipeline Products Glance
    • Ocular Therapeutix, Inc. - Late Stage Pipeline Products
      • Pre-Registration Products/Combination Treatment Modalities
      • Phase III Products/Combination Treatment Modalities
    • Ocular Therapeutix, Inc. - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Ocular Therapeutix, Inc. - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Ocular Therapeutix, Inc. - Drug Profiles
    • dexamethasone acetate SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • travoprost SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • moxifloxacin hydrochloride SR
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Monoclonal Antibody to Inhibit VEGF for Wet Macular Degeneration
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Protein to Inhibit VEGF for Wet Age Related Macular Degeneration
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Ocular Therapeutix, Inc. - Pipeline Analysis
    • Ocular Therapeutix, Inc. - Pipeline Products by Target
    • Ocular Therapeutix, Inc. - Pipeline Products by Route of Administration
    • Ocular Therapeutix, Inc. - Pipeline Products by Molecule Type
    • Ocular Therapeutix, Inc. - Pipeline Products by Mechanism of Action
  • Ocular Therapeutix, Inc. - Recent Pipeline Updates
  • Ocular Therapeutix, Inc. - Locations And Subsidiaries
    • Head Office
    • Other Locations & Subsidiaries
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Ocular Therapeutix, Inc., Key Information
  • Ocular Therapeutix, Inc., Key Facts
  • Ocular Therapeutix, Inc. - Pipeline by Indication, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Stage of Development, 2015
  • Ocular Therapeutix, Inc. - Monotherapy Products in Pipeline, 2015
  • Ocular Therapeutix, Inc. - Pre-Registration, 2015
  • Ocular Therapeutix, Inc. - Phase III, 2015
  • Ocular Therapeutix, Inc. - Phase II, 2015
  • Ocular Therapeutix, Inc. - Phase I, 2015
  • Ocular Therapeutix, Inc. - Preclinical, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Target, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Route of Administration, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Molecule Type, 2015
  • Ocular Therapeutix, Inc. - Pipeline Products by Mechanism of Action, 2015
  • Ocular Therapeutix, Inc. - Recent Pipeline Updates, 2015
  • Ocular Therapeutix, Inc., Other Locations

List of Figures

  • Ocular Therapeutix, Inc. - Pipeline by Top 10 Indication, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Stage of Development, 2015
  • Ocular Therapeutix, Inc. - Monotherapy Products in Pipeline, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Top 10 Target, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Top 10 Route of Administration, 2015
  • Ocular Therapeutix, Inc. - Pipeline by Top 10 Molecule Type, 2015
  • Ocular Therapeutix, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015
Back to Top